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Clinical application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) as first-line treatment of advanced stage non–small-cell lung cancer with 
EGFR mutation is based on vigorous science.1,2 Multiple randomized studies have inde-
pendently confirmed gefitinib and erlotinib to be superior to platinum-based doublet che-
motherapy.3–6 Thus, it is natural to ask if gefitinib is better than erlotinib or vice versa. Lim 
et al.7 addressed this question with a relatively large case-control study of 121 matched 
pairs of gefitinib-treated and erlotinib-treated patients. The pair-matching was appropri-
ately based on gender, smoking history, performance status, and type of EGFR mutations. 
Authors reported similar tumor response rate (76.9% versus 74.4%, p = 0.58) and median 
progression-free survival (PFS) (11.7 versus 9.6 months; p = 0.056) between the gefitinib- 
and erlotinib-treated groups. Based on the data, Lim et al.7 concluded equal effectiveness 
between the two EGFR TKIs. In short of a randomized comparative study, this report pro-
vides a relatively fair picture on the choice between gefitinib and erlotinib.
But how “fair” is this fair comparison? Limited by retrospective nature of this study, 
authors can only take on the required action of patient-pairing to assure similar character-
istics between two groups. However, they have ignored one important factor, which is the 
number of prior treatment(s). As a result, there are significantly more patients receiving first-
line gefitinib than patients with first-line erlotinib. Authors may argue that PFS on first-line 
EGFR TKI is not different from second-/third-line EGFR TKI.8 Truth is that this remains 
assumptive. There are data suggesting that chemotherapy may have significant impact on 
EGFR mutation status.9 Sequential intercalation of chemotherapy and EGFR TKI may also 
potentially improve PFS and overall survival of patients with EGFR mutations.10 Authors 
have also taken the required action of performing contrasted computed tomography scan 
every 8 weeks for assessment of tumor status. But it is unclear how they have followed the 
progress of 83 patients (34% of the 242 enrolled patients) with bone metastasis, knowing 
well that computed tomography scan is not a reliable method of assessment for bone metas-
tasis. Thus, their comparison is fairly fair but not convincingly fair.
We should also address the basic question of why we want to compare gefitinib with 
erlotinib? Both drugs are anilinoquinazolines with similar molecular structure (Figure 1) 
and both drug share similar mechanism of action in binding to EGFR ATP binding pocket. 
Pharmacokinetics of the two drugs is not dramatically different. Main difference between 
the two compounds is the maximum tolerated dose of erlotinib being estimated at 150 mg 
daily while maximum tolerated dose of gefitinib at 700 mg daily (which is much higher 
than the standard prescription dose).11 A network meta-analysis of multiple phase II and 
III studies indicated potential longer PFS associated with erlotinib.12 Value of this type of 
network meta-analysis is controversial, and yet the worthiness of engaging a large random-
ized study to confirm a relatively small difference in PFS between two similar drugs is 
arguable. Furthermore, it is common for doctors to continue EGFR TKI beyond disease 
progression (according to RECIST criteria).13 PFS of erlotinib at OPTIMAL and EURTAC 
study was 13.1 and 9.2 months, respectively, and PFS of gefitinib at IPASS, NEJ002, and 
WJTOG3402 was 9.8, 10.8, and 9.2 months, respectively.2–6 The numeric difference on PFS 
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would have limited clinical implication if majority of patients 
continue with the same EGFR TKI beyond RECIST progres-
sion. In the absence of an objective, measurable, and clinically 
meaningful criteria for comparison, it will be almost impos-
sible to define a better EGFR TKI. Only if we had a magic 
mirror, we might take on the subjective action of identifying 
the fairest of all EGFR TKIs.
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Figure 1.  Molecular structure of gefitinib and 
erlotinib.
